Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant
Abstract
:1. Introduction
2. Results
2.1. Establishment of a Cell Line for Collateral Sensitivity Screen
2.2. Collateral Sensitivity Screen
3. Discussion
4. Materials and Methods
4.1. Cell Lines and Reagents
4.2. Retroviral Transduction Experiments
4.3. Screening Assay
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Zhao, B.; Sedlak, J.C.; Srinivas, R.; Creixell, P.; Pritchard, J.R.; Tidor, B.; Lauffenburger, D.A.; Hemann, M.T. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell 2016, 165, 234–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pemovska, T.; Johnson, E.; Kontro, M.; Repasky, G.A.; Chen, J.; Wells, P.; Cronin, C.N.; McTigue, M.; Kallioniemi, O.; Porkka, K.; et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015, 519, 102–105. [Google Scholar] [CrossRef] [PubMed]
- Shaw, A.T.; Friboulet, L.; Leshchiner, I.; Gainor, J.F.; Bergqvist, S.; Brooun, A.; Burke, B.J.; Deng, Y.-L.; Liu, W.; Dardaei, L.; et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N. Engl. J. Med. 2016, 374, 54–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Young, R.M.; Staudt, L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 2013, 12, 229–243. [Google Scholar] [CrossRef] [PubMed]
- Lucas, F.; Woyach, J.A. Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies. Target. Oncol. 2019, 14, 125–138. [Google Scholar] [CrossRef] [PubMed]
- Byrd, J.C.; Hillmen, P.; O’Brien, S.; Barrientos, J.C.; Reddy, N.M.; Coutre, S.; Tam, C.S.; Mulligan, S.P.; Jaeger, U.; Barr, P.M.; et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019, 133, 2031–2042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woyach, J.A.; Ruppert, A.S.; Guinn, D.; Lehman, A.; Blachly, J.S.; Lozanski, A.; Heerema, N.A.; Zhao, W.; Coleman, J.; Jones, D.; et al. BTKC481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2017, 35, 1437–1443. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woyach, J.A.; Furman, R.R.; Liu, T.-M.; Ozer, H.G.; Zapatka, M.; Ruppert, A.S.; Xue, L.; Li, D.H.-H.; Steggerda, S.M.; Versele, M.; et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 2014, 370, 2286–2294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jain, P.; Keating, M.; Wierda, W.; Estrov, Z.; Ferrajoli, A.; Jain, N.; George, B.; James, D.; Kantarjian, H.; Burger, J.; et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015, 125, 2062–2067. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Warmuth, M.; Kim, S.; Gu, X.; Xia, G.; Adrián, F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 2007, 19, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Li, T.; Tsukada, S.; Satterthwaite, A.; Havlik, M.H.; Park, H.; Takatsu, K.; Witte, O.N. Activation of bruton’s tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 1995, 2, 451–460. [Google Scholar] [CrossRef] [Green Version]
- Di Paolo, J.A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K.H.; Bravo, B.J.; Carano, R.A.D.; Darrow, J.; Davies, D.R.; DeForge, L.E.; et al. Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis. Nat. Chem. Biol. 2011, 7, 41–50. [Google Scholar] [CrossRef] [PubMed]
- Fröhling, S.; Scholl, C.; Levine, R.L.; Loriaux, M.; Boggon, T.J.; Bernard, O.A.; Berger, R.; Döhner, H.; Döhner, K.; Ebert, B.L.; et al. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Cancer Cell 2007, 12, 501–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whittaker, S.; Kirk, R.; Hayward, R.; Zambon, A.; Viros, A.; Cantarino, N.; Affolter, A.; Nourry, A.; Niculescu-Duvaz, D.; Springer, C.; et al. Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies. Sci. Transl. Med. 2010, 2, 35ra41. [Google Scholar] [CrossRef] [PubMed]
- Dogruluk, T.; Tsang, Y.H.; Espitia, M.; Chen, F.; Chen, T.; Chong, Z.; Appadurai, V.; Dogruluk, A.; Eterovic, A.K.; Bonnen, P.E.; et al. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res. 2015, 75, 5341–5354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frecha, C.; Costa, C.; Levy, C.; Negre, D.; Russell, S.J.; Maisner, A.; Salles, G.; Peng, K.-W.; Cosset, F.-L.; Verhoeyen, E. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009, 114, 3173–3180. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Libre, C.; Moro-Sibilot, L.; Giraud, S.; Martin, L.; Verhoeyen, E.; Costa, C.; Chebel, A.; Bissay, N.; Salles, G.; Genestier, L.; et al. Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant. Cancers 2020, 12, 901. https://doi.org/10.3390/cancers12040901
Libre C, Moro-Sibilot L, Giraud S, Martin L, Verhoeyen E, Costa C, Chebel A, Bissay N, Salles G, Genestier L, et al. Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant. Cancers. 2020; 12(4):901. https://doi.org/10.3390/cancers12040901
Chicago/Turabian StyleLibre, Camille, Ludovic Moro-Sibilot, Stéphane Giraud, Laetitia Martin, Els Verhoeyen, Caroline Costa, Amel Chebel, Nathalie Bissay, Gilles Salles, Laurent Genestier, and et al. 2020. "Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant" Cancers 12, no. 4: 901. https://doi.org/10.3390/cancers12040901